The short answer
Watch and wait is standard in early CLL and asymptomatic follicular lymphoma because randomised trials show treating earlier delays progression without helping people live longer.
Watch and wait is standard care in early-stage CLL and in asymptomatic, low-burden follicular lymphoma, not a lesser option.
In follicular lymphoma trials, immediate treatment delayed the need for further therapy but did not improve overall survival.
In the phase III CLL12 trial, ibrutinib clearly delayed progression yet five-year overall survival was 93.3% versus 93.6% with placebo.
CLL12 investigators concluded that watch and wait remains the standard of care irrespective of risk factors.
Choose how you want to understand this
The full explanation.
Being told to do nothing
Some blood cancers are diagnosed and then, deliberately, not treated. You are given a diagnosis, a schedule of blood tests and visits, and no medication. This is called watch and wait, watchful waiting, or active surveillance.
It is standard practice in early-stage chronic lymphocytic leukemia (CLL), in small lymphocytic lymphoma, and in advanced-stage follicular lymphoma that is not causing symptoms and is not bulky. Similar reasoning applies to smoldering myeloma and some low-grade lymphomas.
Most people find it deeply counterintuitive. You have cancer. It is being left alone. That reaction is normal and worth saying out loud to your team.
Why it is done
The reason is not resource rationing, and it is not that you are too well to bother treating. It is that treating earlier has been tested against waiting, repeatedly, and has not been shown to help people live longer.
In follicular lymphoma, randomized trials compared immediate treatment against observation in people with asymptomatic, low-tumor-burden disease. Immediate treatment delayed the point at which further therapy was needed. It did not improve overall survival. A substantial proportion of people on observation went years without needing any treatment at all, and some never needed it.
In CLL, the phase III CLL12 trial randomized people with early-stage, asymptomatic disease to ibrutinib or placebo. Ibrutinib clearly delayed progression (hazard ratio 0.276). Overall survival was essentially identical: 93.3% versus 93.6% at five years. The investigators concluded that "watch and wait remains the standard of care irrespective of risk factors." This was tested with a modern targeted drug, not old chemotherapy, which is what makes the result meaningful.
These diseases are typically not curable with current standard treatment, but they are often controllable for a very long time. Treatments work about as well later as earlier. Starting sooner therefore buys nothing in lifespan, while spending side effects, resistance, and treatment burden that could be saved for when they are needed.
What watch and wait actually involves
It is monitoring, not absence. Expect visits every three to six months initially, sometimes stretching to annually if things stay stable. Expect a complete blood count each time, examination of lymph nodes, spleen, and liver, and questions about symptoms. Imaging is done when there is a reason, not routinely.
Your team is watching for specific triggers. In CLL these commonly include falling hemoglobin or platelets from marrow involvement, rapidly rising lymphocyte counts, spleen or node enlargement causing symptoms, drenching night sweats, unintentional weight loss, persistent fever without infection, or profound fatigue. In follicular lymphoma the triggers include bulky disease, symptoms, marrow failure, and organ compromise.
Knowing the specific triggers helps. Ask what yours are, in plain terms, so that you know what you are watching for and what does not count.
The emotional part
The hardest thing about watch and wait is that it asks you to live alongside a diagnosis without a task. Many people describe feeling more anxious than friends who started treatment immediately. Scan and blood-test anxiety before each visit is extremely common.
Some things that help: knowing your own numbers and trends rather than only being told they are fine; having a defined list of symptoms that warrant an earlier call; scheduling something after each appointment so the day is not only about waiting; and connecting with others in the same position, since this experience is specific and hard to explain to people whose cancer meant immediate treatment.
Practical points
People with CLL have impaired immunity from the disease itself, whether or not they are on treatment. Vaccinations, prompt attention to infections, and skin cancer surveillance matter. Ask what is recommended for you.
If you want a second opinion, the fact that you are not on treatment makes this easier, not harder. There is time.
Worth asking
Ask what specifically would trigger starting treatment. Ask what your prognostic markers are, such as IGHV mutation status, del(17p), or TP53 in CLL, and what they change. Ask which symptoms should prompt a call between visits. Ask what treatment would look like when the time comes, so it is not an unknown.
Sources
Words to know
Tap any term to see what it means.
Common questions
Why am I not being treated if I have cancer?
Because treating earlier has been directly tested against waiting and has not been shown to help people live longer. These diseases are typically controllable rather than curable with standard treatment, and treatments work about as well later as earlier, so starting sooner spends side effects without buying lifespan.
Is this because my case is not serious, or because of cost?
Neither. It is a conclusion from randomised trials. CLL12 tested a modern targeted drug, ibrutinib, against placebo in early-stage disease and found essentially identical survival, which is what makes the result convincing rather than a hangover from the chemotherapy era.
What are they actually watching for?
Specific triggers. In CLL these commonly include falling hemoglobin or platelets, rapidly rising lymphocyte counts, symptomatic enlargement of the spleen or lymph nodes, drenching night sweats, unintentional weight loss, persistent fever without infection, or profound fatigue. In follicular lymphoma, bulky disease, symptoms, marrow failure, and organ compromise. Ask for your own list in plain terms.
Might I never need treatment?
It is possible. In follicular lymphoma observation trials, a substantial proportion of people went years without needing any treatment, and some never required it. Others need treatment sooner. Your monitoring is designed to tell which.
How do I cope with waiting?
Things that help include knowing your own numbers and trends rather than only being told they are fine, having a defined list of symptoms that warrant an earlier call, and connecting with others in the same position, since this experience is hard to explain to people whose cancer meant immediate treatment.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the federal sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Written by: Cancer Explained Editorial TeamSources last checked: 2026-07-30Last updated: 2026-07-30Next planned review: 2027-07-30
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source verified. This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source verified — This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share